0910-AG87 201410 The Regulatory Plan and the Unified Agenda of Federal Regulatory and Deregulatory Actions 0910 Food and Drug Administration FDA 0900 Department of Health and Human Services HHS Blood Initiative--Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use

FDA is amending the regulations applicable to blood and blood components, including Source Plasma, to make the donor eligibility and testing requirements, more consistent with current practices in the blood industry to more closely align the regulations with current FDA recommendations, and to provide flexibility to accommodate advancing technology. These actions are intended to help ensure the continued safety of the Nation's blood supply and to help protect donor health.

]]> Other Significant Previously Published in The Unified Agenda Final Rule Stage Undetermined No 21 CFR 606 21 CFR 610 21 CFR 630 21 CFR 640 21 CFR 660 21 CFR 820 21 USC 321 21 USC 331 21 USC 351 to 353 21 USC 355 21 USC 360 21 USC 360c to 360e 21 USC 360h to 360j 21 USC 360l 21 USC 371 21 USC 372 21 USC 374 21 USC 381 21 USC 383 42 USC 216 42 USC 262 42 USC 263 42 USC 263a 42 USC 264 No NPRM 11/08/2007 72 FR 63416 NPRM Comment Period Extended 01/11/2008 73 FR 1983 NPRM Comment Period End 02/06/2008 NPRM Comment Period Extended End 08/04/2008 Final Action 03/00/2015 No Businesses None No No No No Valerie Butler A. Team Leader 0910 Food and Drug Administration FDA 240 402-7911 301 595-1310 Center for Biologics Evaluation and Research, 10903 New Hampshire Avenue, Building 71, Silver Spring MD 20903-0002